Literature DB >> 18574262

Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Gordon H Guyatt1, Deborah J Cook2, Roman Jaeschke3, Stephen G Pauker4, Holger J Schünemann5.   

Abstract

This chapter describes the system used by the American College of Chest Physicians to grade recommendations for antithrombotic and thrombolytic therapy as part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Clinicians need to know if a recommendation is strong or weak, and the methodologic quality of the evidence underlying that recommendation. We determine the strength of a recommendation by considering the balance between the desirable effects of an intervention and the undesirable effects (incremental harms, burdens, and for select recommendations, costs). If the desirable effects outweigh the undesirable effects, we recommend that clinicians offer an intervention to typical patients. The uncertainty associated with the balance between the desirable and undesirable effects will determine the strength of recommendations. If we are confident that benefits do or do not outweigh harms, burden, and costs, we make a strong recommendation in our formulation, Grade 1. If we are less certain of the magnitude of the benefits and risks, burden, and costs, and thus their relative impact, we make a weaker Grade 2 recommendation. For grading methodologic quality, randomized controlled trials (RCTs) begin as high-quality evidence (designated by "A"), but quality can decrease to moderate ("B"), or low ("C") as a result of poor design and conduct of RCTs, imprecision, inconsistency of results, indirectness, or a high likelihood for reporting bias. Observational studies begin as low quality of evidence (C) but can increase in quality on the basis of very large treatment effects. Strong (Grade 1) recommendations can be applied uniformly to most patients. Weak (Grade 2) suggestions require more judicious application, particularly considering patient values and preferences and, when resource limitations play an important role, issues of cost.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574262     DOI: 10.1378/chest.08-0654

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  41 in total

1.  Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; Holger J Schünemann; David D Gutterman; Sandra Zelman Lewis
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Paracetamol versus placebo for knee and hip osteoarthritis.

Authors:  Amanda O Leopoldino; Gustavo C Machado; Paulo H Ferreira; Marina B Pinheiro; Richard Day; Andrew J McLachlan; David J Hunter; Manuela L Ferreira
Journal:  Cochrane Database Syst Rev       Date:  2019-02-25

Review 3.  What you should know about the 2008 American College of Chest Physicians evidence-based clinical practice guidelines (8th) on antithrombotic and thrombolytic therapy.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

4.  Clarity and applicability of drug-drug interaction management guidelines: a systematic appraisal by general practitioners and community pharmacists in the Netherlands.

Authors:  Annemieke Floor-Schreudering; Peter A G M De Smet; Henk Buurma; Sonia Amini; Marcel L Bouvy
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

Review 5.  The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Wendy Lim; Sara K Vesely; James N George
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

6.  [Not Available].

Authors:  S Siah; A El Farouki
Journal:  Ann Burns Fire Disasters       Date:  2014-06-30

7. 

Authors:  Sean Wharton; David C W Lau; Michael Vallis; Arya M Sharma; Laurent Biertho; Denise Campbell-Scherer; Kristi Adamo; Angela Alberga; Rhonda Bell; Normand Boulé; Elaine Boyling; Jennifer Brown; Betty Calam; Carol Clarke; Lindsay Crowshoe; Dennis Divalentino; Mary Forhan; Yoni Freedhoff; Michel Gagner; Stephen Glazer; Cindy Grand; Michael Green; Margaret Hahn; Raed Hawa; Rita Henderson; Dennis Hong; Pam Hung; Ian Janssen; Kristen Jacklin; Carlene Johnson-Stoklossa; Amy Kemp; Sara Kirk; Jennifer Kuk; Marie-France Langlois; Scott Lear; Ashley McInnes; David Macklin; Leen Naji; Priya Manjoo; Marie-Philippe Morin; Kara Nerenberg; Ian Patton; Sue Pedersen; Leticia Pereira; Helena Piccinini-Vallis; Megha Poddar; Paul Poirier; Denis Prud'homme; Ximena Ramos Salas; Christian Rueda-Clausen; Shelly Russell-Mayhew; Judy Shiau; Diana Sherifali; John Sievenpiper; Sanjeev Sockalingam; Valerie Taylor; Ellen Toth; Laurie Twells; Richard Tytus; Shahebina Walji; Leah Walker; Sonja Wicklum
Journal:  CMAJ       Date:  2020-12-07       Impact factor: 8.262

8.  [Thrombosis prophylaxis in geriatric patients].

Authors:  R E Roller; P Feichtinger
Journal:  Z Gerontol Geriatr       Date:  2012-04       Impact factor: 1.281

Review 9.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 10.  Use of anticoagulants in elderly patients: practical recommendations.

Authors:  Helia Robert-Ebadi; Grégoire Le Gal; Marc Righini
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.